Articles tagged with Cell Therapies
This study explored the immune dynamics across different phases of HBV infection, identifying key factors influencing T cell function and liver priming. The research team uncovered distinct types of intrahepatic T lymphocytes and dual roles of DC-SIGN+ macrophages in modulating immune responses.
Researchers at MIT developed a control circuit that can precisely regulate gene expression levels, improving the efficacy and safety of gene therapy treatments. The 'COMMAND' circuit uses microRNA to suppress gene expression, allowing for tighter control over treatment outcomes.
A Phase Ia/Ib trial found that zongertinib demonstrated clinical benefits for patients with advanced HER2-mutant non-small cell lung cancer, particularly those with specific HER2 mutations. The treatment showed a 71% objective response rate and manageable side effects.
A clinical trial found that LUT014, a topical BRAF inhibitor, significantly reduced the severity of acne-like skin rashes caused by targeted therapy for colorectal cancer. Patients who received LUT014 had improved quality of life and were able to continue receiving their cancer treatment with reduced side effects.
Researchers develop nanoparticle-based therapy combining hydroxyl-enriched fullerenol and mTOR inhibitors to disrupt cancer cells' organelle communication system. The approach triggers a synergistic "nanomaterial + metabolic modulation" anticancer strategy, establishing a new hope for treating aggressive cancers.
A novel topical BRAF inhibitor gel called LUT014 has been shown to significantly reduce the severity of an acne-like rash in patients undergoing anti-EGFR therapies for colorectal cancer. The treatment's safety and effectiveness have been confirmed, offering a potential solution to managing this common side effect.
The treatment demonstrated early signals of efficacy, with 65.7% of patients experiencing lasting stable disease, and was generally well-tolerated, with most adverse events being mild and manageable.
Researchers at Northwestern University propose a new approach to therapeutic development using structural precision in nanomedicine. By fine-tuning the interaction between nanomedicines and the human body, scientists can design interventions that are more effective, targeted, and beneficial for patients.
A new study reports on five patients with Canavan disease who have a novel variant identified through targeted long-read sequencing, revealing an SVA_E retrotransposable element that disrupts gene function. The findings enhance genetic diagnostics and enable improved guidance for families.
Researchers at MD Anderson Cancer Center present promising results from clinical trials in three minisymposia abstracts. The studies explore personalized vaccine combination therapy for colorectal cancer, radiotherapy to avoid toxicities of systemic treatments for kidney cancer, and engineered exosomes to silence mutant KRAS in pancrea...
A phase 1 trial involving 40 patients showed significant responses to the new cell therapy IMA203, with half of non-responders achieving lasting response. The therapy targets PRAME peptide produced by many tumors and was well-tolerated.
A new machine learning model accurately predicts the fitness of AAV capsids based on their amino acid sequence, enabling more efficient and cost-effective gene therapies. The model's robustness and generalizability have been demonstrated through tests on independent datasets, offering a promising tool for capsid engineering.
Researchers from the UCLA Health Jonsson Comprehensive Cancer Center are presenting new findings on combination therapies for liver and pancreatic cancers, including a new organoid model for personalized head and neck cancer treatment. Additionally, they are discussing the potential of liquid biopsies for cancer detection and monitoring.
Researchers have uncovered the molecular mechanism of ATG-9 in regulating lysosome integrity by modulating phospholipid distribution. This study suggests that reduced ATG-9 scramblase activity facilitates lysosome biogenesis and repair, highlighting ATG-9 as a promising therapeutic target for diseases related to lysosomal dysfunction.
Researchers discovered that endoperoxides derived from ergosterol and 7-dehydrocholesterol induce the death of melanoma cells. This finding paves the way for expanding the use of photodynamic therapy in fighting skin cancer.
A study reveals that Galectin-1 protein, located in fibroblast nuclei, promotes tumor growth and resistance to treatment. The protein regulates gene expression at a specific level, activating KRAS, a key driver of uncontrolled growth and tumor aggressiveness.
Researchers discovered that aging causes inflammation, oxidative stress, and gene disruption in the retinal pigment epithelium, a vital layer of cells in the eye. This study provides a clearer understanding of why aging leads to eye disease and introduces a reliable laboratory model for testing new therapies.
Researchers have developed an innovative optical genome mapping technique that can identify structural variants and copy number variations across the entire genome in a single test. The method has been shown to reduce material requirements and improve prognostic stratification for patients with multiple myeloma.
A new method using UV light and machine learning can detect microbial contamination in cell cultures, providing a quicker yes/no assessment within 30 minutes. This technology aims to reduce the time spent on sterility tests, making it crucial for life-saving treatments.
Researchers used CRISPR interference to examine every gene in the human genome and discovered a new set of genes contributing to Parkinson's disease risk. The study identified the Commander complex, which regulates lysosomal function and is implicated in PD risk, offering opportunities for new treatments.
Researchers at Moffitt Cancer Center have found that a natural protein called CD40L can improve the speed and success of TIL manufacturing, potentially benefiting more patients. The study showed that CD40L-enhanced TILs grew successfully in 67% of samples when used, compared to 33% without it.
Researchers found that GSK3β becomes increasingly active in melanoma cells during treatment, helping them survive and adapt despite BRAF inhibitors. Treating resistant cancer cells with a GSK3β inhibitor significantly reduced their growth, suggesting blocking this protein could restore sensitivity to treatment.
Researchers have identified Tim-3 as a promising therapeutic target for Alzheimer's disease by targeting microglia in the brain. Deleting Tim-3 helps kickstart plaque removal, reduce neuroinflammation, and limit cognitive impairment.
Researchers have developed a new approach to overcome treatment resistance in estrogen receptor-positive (ER+) breast cancer. Dual aromatase-steroid sulfatase inhibitors (DASIs) show promise in effectively blocking both enzymes involved in oestrogen production, potentially reducing tumour growth.
STITCHR uses an RNA system to replace entire genes, overcoming CRISPR limitations in targeting every mutation. The tool offers a one-and-done approach for gene therapy, addressing cystic fibrosis and other diseases with thousands of mutations.
A phase 1 clinical trial will evaluate the safety and efficacy of CLBR001 + SWI019 in patients with myositis, systemic sclerosis, lupus and rheumatoid arthritis. The therapy has the potential to reduce side effects and patient burden associated with traditional CAR-T approaches.
Researchers developed a dual-action nanotherapy that converts white fat into beige fat and reduces obesity-related inflammation, significantly improving metabolic health without detectable toxicity.
Scientists have discovered a novel regulator of the mitochondrial sodium-calcium exchanger (NCLX), which helps maintain calcium balance in mitochondria. The discovery of TMEM65 could lead to new therapeutic agents to combat calcium overload associated with heart failure and Alzheimer's disease.
Neuro-immunologist Stephen Hauser has won the 2025 Breakthrough Prize in Life Sciences for his role in identifying the immune system's primary driver of damage to nerve cells in multiple sclerosis. His B-cell theory has led to the development of therapies that have transformed treatment, reducing relapses and improving prognosis.
Researchers at Cornell University have discovered key neurological mechanisms in psilocybin's brain effects, targeting pyramidal tract neurons and serotonin receptors. This could enable pharmaceuticals to deliver mood-altering benefits while suppressing perceptual hallucinations.
Researchers found that combining imipridones with radiation therapy and temozolomide slowed glioblastoma growth and prolonged survival in mice. The treatment also boosted immune responses and suppressed MGMT protein expression, making it more effective.
Researchers have discovered a key cellular mechanism regulating mRNA vaccine delivery and stability, proposing a new paradigm for mRNA therapeutics. The study highlights the importance of N1-methylpseudouridine modification in enhancing mRNA vaccine effectiveness.
Researchers found that NSD2 helps maintain MM cell identity by reorganizing DNA and influencing gene activity. This discovery could shape future treatment approaches for patients with t(4;14) myeloma.
A new study suggests that blood cancer patients receiving Bruton Tyrosine Kinase inhibitors should continue their therapy while getting vaccinated against COVID-19. The IMPROVE trial found no improvement in antibody responses when BTKi therapy was paused for three weeks around the time of vaccination.
A team of Chinese researchers identified a novel intercellular signaling mechanism between adipocytes and hepatocytes in endoplasmic reticulum stress response. The study reveals that ceramide, a fat molecule, plays a key role in activating the unfolded protein response pathway in hepatocytes.
A machine-learning algorithm named catGRANULE 2.0 ROBOT identifies molecular targets for further researches and therapies in neurodegenerative diseases. The algorithm analyzes protein-RNA interaction to predict potential harm and identify early pathological signals.
Researchers at Cornell University discovered that the FGR protein can induce cell differentiation in leukemia cells similar to retinoic acid treatment. The presence of FGR alone was enough to make these cells mature, producing well-known markers of maturation and expressing inhibitor of the cell cycle p27.
A recent study by the CNIO Melanoma Group has discovered a mechanism by which melanomas evade immune system surveillance. The research found that melanoma cells secrete Midkine, a protein that reduces dendritic cell numbers and reprograms their function to promote tumour development.
Researchers discovered TBX2 drives therapy resistance by shifting signaling from the androgen receptor to the glucocorticoid receptor. The study identified a strategy to target this switch, potentially predicting patient risk and offering new treatment approaches.
Researchers at MD Anderson Cancer Center made several key discoveries, including the spatial organization of cancer-associated fibroblasts across various cancers and a study on treatment resistance in SMARCA4-mutant lung cancer. These findings highlight the importance of investigating cell populations in their spatial context to better...
A team of scientists has created a new method to selectively modify specific proteins in complex biological environments. They achieved this using aptamers and deoxyoxanosine, allowing precise conjugation of desired sites on target proteins. This breakthrough technology has the potential to revolutionize cancer diagnosis and treatment.
A new review highlights how breast cancer cells change their communication and growth patterns, helping tumors survive, spread, and resist treatment. The review explores disrupted signaling pathways, including PI3K/Akt/mTOR and RAS/RAF/MEK/ERK, which can promote tumor progression and resistance to treatment.
Researchers have discovered a potential new treatment for pulmonary fibrosis by targeting the Piezo2 receptor, which plays a critical role in stiffness-mediated profibrotic fibroblast phenotypes. Inhibiting Piezo2 expression or function may slow disease progression and offer new therapeutic options.
Researchers have developed a TIM-3 decoy that improves the effectiveness of CAR-T cell therapy in treating B-cell Acute Lymphoblastic Leukemia. The decoy blocks the interaction between the tumor and immune cells, allowing CAR-T cells to persist and attack cancer cells more effectively.
Scientists from the University of Zurich created decoy molecules that bind to autoantibodies, preventing them from inhibiting type I interferons. This restoration restores antiviral effect on viruses like influenza, offering hope for treatment and reducing viral disease susceptibility.
A new study found that recombinant adeno-associated virus (rAAV) capsids contain single-stranded DNA impurities derived from plasmid and host cell DNA. The researchers suggest that the adverse effects of these impurities may differ from those of double-stranded DNA, highlighting the need for further evaluation.
A new editorial highlights a growing concern in cancer care: radiotherapy may leave behind residual disease that can lead to worse long-term outcomes. Studies have shown that patients with residual disease are more likely to experience cancer recurrence and shorter survival, emphasizing the need for regular biopsy-based tests.
Breast cancer survivors experience accelerated aging due to detrimental effects of BC and its treatments, particularly systemic therapies. The study highlights the need for ongoing monitoring and potential strategies to slow down aging in cancer survivors.
Dr. Nowicki's team has engineered 'supercharged' T cells that produce extra TNF-alpha to boost cancer-fighting ability, offering a potentially more precise and toxic-free treatment option. The new funding will help test these enhanced T cells in preclinical models to evaluate their effectiveness.
Researchers identified PDGFRA as a promising therapeutic target for pediatric high-grade gliomas. Inhibition of the PDGFRA signaling pathway leads to tumor cell death and has shown potential in laboratory and animal models, as well as initial clinical experience with avapritinib therapy.
A research team from UH Seidman Cancer Center developed an ultra-fast and highly scalable CAR T-cell therapy manufacturing platform, enabling wider utilization of the therapy. The approach resulted in significantly more favorable toxicity profiles compared to traditional CAR-T products.
Researchers have discovered how severe COVID-19 can destroy immune cells' ability to repair the lungs, leading to lingering effects of long COVID. By enhancing damaged organelles using a FDA-approved drug, they found improved lung healing and reduced inflammation.
Researchers found that semisynthetic bile acid NorUDCA inhibits pro-inflammatory T helper 17 cells and promotes anti-inflammatory regulatory T cells in the intestine. This could lead to new therapies for inflammatory bowel diseases such as ulcerative colitis or Crohn's disease.
Researchers at H. Lee Moffitt Cancer Center & Research Institute have discovered a new way to boost cancer immunotherapy by targeting the MARCO protein, which significantly enhances tumor regression in melanoma. This approach could help overcome resistance to current treatments and improve outcomes for patients with treatment-resistant...
Engineered platelets-based nano-aircraft carriers enhance targeted chemotherapy with graded drug release, promoting antitumor immune response and reducing metastasis. Researchers successfully develop Pts-based nanovesicles for precise cancer treatment.
A new type of antibody that stimulates the immune system to target cancer cells has shown promise in reducing tumor growth in treatment-resistant breast and ovarian cancers. The study found that the antibody, IgE, uniquely stimulated otherwise inactive immune cells to directly target HER2-expressing cancer cells.
A study co-led by the University of Zurich has shown that gluconolactone significantly increases the number and function of regulatory T cells in both mice and humans, promoting a more balanced immune environment. This effect was observed in lupus patients as well, with visible improvements in clinical studies after just two weeks.
The study highlights the role of the Nwd1 gene in liver disease and its potential as a therapeutic target. Mice with Nwd1 gene deletion exhibited liver pathologies mirroring MASH, including excessive lipid accumulation and increased ER stress.
Researchers used CRISPR to cut a single gene from cancer cells of head and neck tumors, resulting in the elimination of 50% of the tumors after 84 days. This groundbreaking study demonstrates that some genes are essential for cancer cell survival, making them excellent targets for CRISPR therapy.
Researchers found that PRP treatment increased gene expression related to metabolism, cell survival, and communication between cells in cumulus cells. This suggests that PRP may help support egg development and fertility in women with poor ovarian response.